The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Empowering Innovation: Clinical Trials Reform Strategies by EMA for 2025

By João L. Carapinha

September 29, 2025

The recently published European Medicines Agency (EMA) article addresses the strategic targets for improving the clinical trials reform landscape in Europe. It emphasizes measures that foster innovation, collaboration, and efficiency in clinical research. The article outlines new priorities for 2...
Biosimilars Market Trends 2025: Understanding Erosion and Growth

By Rene Pretorius

September 26, 2025

This article explores how biosimilars market trends are transforming the biologics market, making treatments more affordable and reshaping competition. Drawing from a 2022 comparative analysis of US, Germany, and Switzerland markets (2011–2020) [1] and updated 2024–2025 data [2-4] it...
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control

By João L. Carapinha

September 25, 2025

The article by Kate Bowie at the BMJ (linked below) highlights NHS productivity gains, reporting a 2.7% year-on-year increase in hospital efficiency for 2024–25 compared with a 3% rise in costs. This improvement is attributed to measures such as shorter hospital stays, reduced ag...